PARIS--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Paris:MKEA)(Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary optical biopsy platform, today announced that the Haute Autorité de Santé (HAS) - or French High Authority for Health, has delivered a favorable opinion for the inclusion of Cellvizio on the list of reimbursable procedures for use in patients with Barrett’s Esophagus. Barrett’s Esophagus is a pathology that must be closely monitored to detect if cancer of the esophagus has developed.
Help employers find you! Check out all the jobs and post your resume.
